In this episode of Inside the Mind of a BioTech Builder, Yves Decadt goes past the hype and into the real-world impact and constraints of AI in healthcare. Rather than treating AI as a magic solution, he examines where it is already changing the game — in discovery, diagnostics, delivery, and patient engagement — and where expectations are still far ahead of reality.

Drawing on his experience across big pharma, biotech start-ups and investment advisory roles, Yves unpacks how AI can accelerate development cycles, reduce waste, and improve decision-making — but only when it is grounded in data quality, robust clinical thinking, and regulatory awareness. He explores the friction points between engineers, clinicians, and regulators; the ethical and bias risks that can’t be ignored; and what it takes for AI solutions to move from clever prototypes to trusted tools in care pathways.

This episode is not about “AI will change everything.” It’s about where AI is genuinely investable today, where it still needs proof, and how leadership, governance and capital discipline will decide who wins in the next decade of AI-enabled healthcare.

In this opening episode of Inside the Mind of a BioTech Builder, Yves Decadt sets the stage for where biotech is heading next: the convergence of biology, sustainability and long-horizon capital. Rather than treating “green biotech” as a catchphrase, he breaks down what it actually means in practice — from new materials and processes that reduce environmental burden, to platform technologies that can align patient outcomes, planetary impact and investor returns.

Drawing on his 25+ years across Johnson & Johnson, venture-backed biotech, and his advisory work on the initial biotech strategy for NEOM under the Public Investment Fund, Yves explores how the next wave of biotech value creation will be shaped by:

• Shifting regulatory and societal expectations around sustainability,

• The kinds of science and platforms that are most likely to attract serious capital,

• And the difference between stories that “sound green” and businesses that can genuinely scale.

This episode is not about hype cycles. It’s about how founders, boards and investors can read the signal in the green biotech space — understanding where the real opportunities lie, what risks are often underestimated, and how disciplined, ethics-aware leadership can turn sustainability from a marketing angle into a durable investment thesis.

“Inside the Mind of a BioTech Builder is Yves Decadt’s flagship signal to the market — a series that shows what happens when deep-science fluency, pharma and start-up operating experience, and sovereign-level strategy are combined into a leadership system that turns breakthrough biology into real-world, investable impact.”

Yves Decadt didn’t learn leadership from a manual. He forged it across 25+ years in global pharma, biotech and deep-tech — from 18 years at Johnson & Johnson in Europe and the US, to leading Medimetrics (a Philips spin-out developing the first electronic pill and intra-gut microbiome sampling tool), steering Stragen Pharma and SkyePharma, founding BioLingus and taking it to SEC-approved IPO readiness, and helping shape the initial biotech strategy for NEOM under the Public Investment Fund.
Episode 0 sets the stage: why green biotech is a real investment frontier, how AI in healthcare moves from hype to impact, and what truly changes when a corporate executive becomes the “Chief Everything Officer” of a start-up or scale-up.